No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
HK Stock MarketDetailed Quotes
02348 DAWNRAYS PHARMA
- 1.210
- 0.0000.00%
Not Open Dec 20 16:08 CST
1.82BMarket Cap2.94P/E (TTM)
0.000High0.000Low0Volume1.210Open1.210Pre Close0.00Turnover0.00%Turnover Ratio5.04P/E (Static)1.50BShares1.40052wk High0.51P/B1.82BFloat Cap0.92052wk Low0.08Dividend TTM1.50BShs Float3.222Historical High0.080Dividend LFY0.00%Amplitude-0.940Historical Low--Avg Price4000Lot Size6.61%Div YieldTTM6.61%Div Yield LFY
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Chairman Li Qiling increased his Shareholding in DAWNRAYS PHARMA (02348) by 0.184 million shares at a price of 1.2 Hong Kong dollars per share.
On December 13, Chairman Li Qiling increased his Shareholding in DAWNRAYS PHARMA (02348) by 0.184 million shares, at a price of 1.2 Hong Kong dollars per share, for a total amount of 0.2208 million Hong Kong dollars.
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Express News | CITIC Construction Investment: Optimistic about investment opportunities in the pharmaceutical industry in 2025, focusing on new volume and industry integration opportunities
Express News | The tenth batch of national centralized procurement will open bids in Shanghai tomorrow: involving 62 varieties, with strict measures to prevent companies from colluding and manipulating the bidding.
Is the bearish impact fading? Hong Kong stocks in the pharmaceutical sector are collectively strengthening, with wuxi bio rising over 9% and wuxi apptec rising over 7%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
Trending HK Stocks
HK Dividend Stocks HK Dividend Stocks
Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data. Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data.